Printer Friendly

IVAX WILL VIGOROUSLY DEFEND KNOLL LAWSUIT

 IVAX WILL VIGOROUSLY DEFEND KNOLL LAWSUIT
 MIAMI, Oct. 8 /PRNewswire/ -- IVAX Corporation (AMEX: IVX) announced


today that Knoll A.G. and Knoll Pharmaceuticals filed a complaint in the United States District Court for the District of New Jersey against IVAX and its wholly owned subsidiaries, Baker Norton Pharmaceuticals, Inc., and Goldline Laboratories, Inc. The complaint alleges that IVAX' 240 mg. verapamil HCL ER tablets infringe on Knoll's trademark and trade dress, and that the manufacturing process used by IVAX to produce verapamil infringes on a patent issued to Knoll.
 Verapamil HCL ER, which is a sustained release product administered once per day for the treatment of hypertension, is a generic equivalent of a product marketed by Knoll under the brand name Isoptin(R) SR. G.D. Searle & Co. also markets the product under the brand name Calan(R) SR. Calan(R) is a registered trademark of G.D. Searle & Co., and Isoptin(R) SR is a registered trademark of Knoll Pharmaceuticals.
 Baker Norton Pharmaceuticals received approval from the United States Food and Drug Administration of its Abbreviated New Drug Application for 240 mg. verapamil HCL ER on July 3, 1992. The product is distributed by Goldline Laboratories, Inc.
 IVAX is currently reviewing the allegations made in the complaint with counsel. Richard C. Pfenniger Jr., IVAX' senior vice president -- legal affairs and general counsel, stated that, "IVAX considers the complaint to be a nuisance suit, and it will vigorously defend the allegations in the complaint."
 IVAX Corporation is a holding company with subsidiaries involved in specialty chemicals, pharmaceuticals and medical diagnostics. IVAX' principal subsidiaries include Baker Norton Pharmaceuticals, Inc., a developer and marketer of unique brand name pharmaceuticals; Norton Healthcare Limited, a leading manufacturer and marketer of off-patent pharmaceuticals in the United Kingdom, Ireland and other countries; Goldline Laboratories, Inc., a national marketer of off-patent prescription and over-the-counter pharmaceuticals in the United States; Baker Cummins Dermatologicals, Inc., a dermatological products company; Flori Roberts, Inc., a skin care and cosmetics company; DVM Pharmaceuticals Inc., a veterinary products company; Diamedix Corporation, a medical diagnostics company; Delta Biologicals S.r.l., a marketer of medical diagnostic tests and instruments in Italy; and IVAX Industries, Inc., a chemical specialties business.
 -0- 10/8/92
 /CONTACT: Richard C. Pfenniger Jr., senior vice president of legal affairs of IVAX Corporation, 305-590-2309/
 (IVX) CO: IVAX Corporation; Knoll A.G.; Knoll Pharmaceuticals ST: Florida IN: MTC SU:


JJ-JB -- FL010 -- 8047 10/08/92 16:22 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 8, 1992
Words:407
Previous Article:SERVICE MERCHANDISE COMPANY, INC. ANNOUNCES THIRD QUARTER RESULTS
Next Article:DON'T LET THE BIG APPLE TAKE A BITE OUT OF YOU


Related Articles
IVAX CONTINUES TO MANUFACTURE AND DISTRIBUTE VERAPAMIL
/C O R R E C T I O N -- IVAX WILL VIGOROUSLY DEFEND KNOLL LAWSUIT/
IVAX AND KNOLL ANNOUNCED SETTLEMENT OF VERAPAMIL LITIGATION
IVAX ANNOUNCES SETTLEMENT OF VERAPAMIL LITIGATION
IVAX COMMENTS ON LAWSUIT FILED BY JAMES SWEENEY
IVAX AND KNOLL AG EXECUTE LETTER OF INTENT RELATING TO EUROPEAN JOINT VENTURE FOR GENERIC PHARMACEUTICALS
IVAX AND BASF ESTABLISH GENERIC PHARMACEUTICALS JOINT VENTURE IN EUROPE
IVAX COMMENTS ON PATENT SUIT FILED BY ELI LILLY
IVAX And Knoll Establish New Business Alliance In Europe
Knoll Pharmaceutical Company Statement Concerning Synthroid(R) Lawsuit Filed in U.S. District Court, San Francisco

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters